Company Analysis
Sign in

Mustang Bio, Inc. (MBIO)

Nasdaq: MBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.0
◀ Past 3.4● Present 4.4▶ Future 6.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$1.9M+87.8%
Earnings per share$-0.39+99.0%
Operating cash flow-$5.3M+53.9%
Cash$17.3M+152.5%
Debtn/a
Shareholders’ equity$9.5M+346.0%
Shares, diluted4,908,164+705.0%
Return on equity-20.2%
The recordfrom its filings
Filings in 202610
Newest filingNov 5 · S-8
Annual reportMar 19, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$3.5MCash from operations -$4.6Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 15, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
May 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Apr 27, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Apr 17, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Mar 19, 2026 · SEC EDGAR · Form 10-K
Annual report
Open the filing on sec.gov
Jan 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton MBIO · research, not advice